Sugi Predict

Sugi Predict / Compounds / SCHEMBL4591392

SCHEMBL4591392

SCHEMBL4591392

ClCC1CNc2ccc3ccccc3c21

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ TP53 P04637 4/20 0.40
▸ MAPT P10636 4/20 0.36
▸ ALDH1A1 P00352 4/20 0.36
▸ KDM4E B2RXH2 2/20 0.36
▸ POLB P06746 2/20 0.36
▸ HPGD P15428 1/20 0.36
▸ SMN1; SMN2 Q16637 1/20 0.36
▸ AR P10275 6/20 0.35
▸ KLK3 P07288 2/20 0.35
▸ CYP2A6 P11509 1/20 0.34
▸ TSHR P16473 1/20 0.34
▸ HSD17B10 Q99714 1/20 0.34
▸ TDP1 Q9NUW8 1/20 0.34
▸ GAA P10253 2/20 0.34
▸ MEN1 O00255 1/20 0.34
▸ HTT P42858 1/20 0.34
▸ KMT2A Q03164 1/20 0.34
▸ NPSR1 Q6W5P4 1/20 0.34
▸ NR4A1 P22736 1/20 0.34
▸ LMNA P02545 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18430001 0.77 ADH1A (0.36) MAPTALDH1A1KDM4EHPGDTSHR
SCHEMBL31413355 0.75 ADH1A (0.45) HTTLMNA
SCHEMBL31413354 0.75 ADH1A (0.45) HTTLMNA
SCHEMBL13293994 0.75 ADH1A (0.45) HTTLMNA
SCHEMBL9885494 0.75 ADH1A (0.45) HTTLMNA
SCHEMBL4590034 0.75 ADH1A (0.32) KDM4EPOLBHTT
SCHEMBL584232 0.75 ADH1A (0.45) HTTLMNA
SCHEMBL16877012 0.75 MAPT (0.40) TP53MAPTALDH1A1KDM4EPOLB
Hydrochloric Acid SCHEMBL30944523 0.74 ADH1A (0.44) HTTLMNA
SCHEMBL6630128 0.72 CCKBR (0.42) GAAMEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 161 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2024173565-A2 HUMAN SYNTHETIC ANTIBODIES TARGETING HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2 (HER2) MUTANTS NEW YORK UNIVERSITY (US) 2024-08-22 — — WO claimed
EP-3362100-B1 HINDERED DISULFIDE DRUG CONJUGATES GENENTECH INC (US) 2022-06-22 — — EP claimed
US-11286302-B2 Anti-B7-H4 antibodies and immunoconjugates GENENTECH, INC. (US) 2022-03-29 — — US claimed
CN-107001479-B anti-HER 2 antibodies and immunoconjugates 基因泰克公司 2021-09-28 — — CN claimed
CN-108472384-B Hindered disulfide drug conjugates 基因泰克公司 2021-09-24 — — CN claimed
CN-106804108-B anti-B7-H4 antibodies and immunoconjugates 基因泰克公司 2021-08-10 — — CN claimed
EP-3782654-A1 ANTI-HER2 ANTIBODIES AND IMMUNOCONJUGATES Genentech, Inc. (US) 2021-02-24 — — EP claimed
EP-3191135-B1 ANTI-HER2 ANTIBODIES AND IMMUNOCONJUGATES GENENTECH INC (US) 2020-08-19 — — EP claimed
US-20200255539-A1 Anti-HER2 Antibodies and Immunoconjugates GENENTECH, INC. 2020-08-13 — — US claimed
US-10729738-B2 Hindered disulfide drug conjugates GENENTECH, INC. (US) 2020-08-04 — — US claimed
EP-3191135-A1 ANTI-HER2 ANTIBODIES AND IMMUNOCONJUGATES Genentech, Inc. (US) 2017-07-19 — — EP claimed
EP-3191518-A1 ANTI-B7-H4 ANTIBODIES AND IMMUNOCONJUGATES Genentech, Inc. (US) 2017-07-19 — — EP claimed
US-20170112891-A1 HINDERED DISULFIDE DRUG CONJUGATES GENENTECH INC (US) 2017-04-27 — — US claimed
WO-2017064675-A1 HINDERED DISULFIDE DRUG CONJUGATES GENENTECH, INC. (US) 2017-04-20 — — WO claimed
US-20160159910-A1 ANTI-B7-H4 ANTIBODIES AND IMMUNOCONJUGATES GENENTECH, INC. (US) 2016-06-09 — — US claimed
US-20160130358-A1 CYSTEINE ENGINEERED ANTIBODIES AND CONJUGATES GENENTECH, INC. (US) 2016-05-12 — — US claimed
US-20160096893-A1 ANTI-HER2 ANTIBODIES AND IMMUNOCONJUGATES GENENTECH, INC. (US) 2016-04-07 — — US claimed
WO-2016040856-A2 CYSTEINE ENGINEERED ANTIBODIES AND CONJUGATES GENENTECH, INC. (US) 2016-03-17 — — WO claimed
WO-2016040724-A1 ANTI-B7-H4 ANTIBODIES AND IMMUNOCONJUGATES GENENTECH, INC. (US) 2016-03-17 — — WO claimed
WO-2016040723-A1 ANTI-HER2 ANTIBODIES AND IMMUNOCONJUGATES GENENTECH, INC. (US) 2016-03-17 — — WO claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160159910-A1 ANTI-B7-H4 ANTIBODIES AND IMMUNOCONJUGATES CD44, NECTIN4, H1-4 TP53 1117/4885MAPT 2458/4885ALDH1A1 2342/4885
US-11286302-B2 Anti-B7-H4 antibodies and immunoconjugates CD44, NECTIN4, H1-4 TP53 1117/4885MAPT 2458/4885ALDH1A1 2342/4885
US-20160096893-A1 ANTI-HER2 ANTIBODIES AND IMMUNOCONJUGATES ERBB2, EGFR, ERBB3 TP53 56/4885MAPT 1689/4885ALDH1A1 3337/4885
US-20200255539-A1 Anti-HER2 Antibodies and Immunoconjugates ERBB2, EGFR, ERBB3 TP53 56/4885MAPT 1689/4885ALDH1A1 3337/4885
US-10729738-B2 Hindered disulfide drug conjugates STS, TST, SCLY TP53 2240/4885MAPT 2875/4885ALDH1A1 143/4885
US-20160130358-A1 CYSTEINE ENGINEERED ANTIBODIES AND CONJUGATES GCLC, CTH, CBS TP53 74/4885MAPT 1987/4885ALDH1A1 1572/4885
US-20170112891-A1 HINDERED DISULFIDE DRUG CONJUGATES STS, TST, SCLY TP53 2240/4885MAPT 2875/4885ALDH1A1 143/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.